Anadis to sell Travelan in USA
Wednesday, 12 October, 2005
Melbourne biopharmaceutical company Anadis (ASX:ANX) has received legal advice that its over-the-counter traveller's diarrhoea product, Travelan, complies with all US federal and state regulations for sale in the dietary and medical foods categories.
Anadis is currently in discussions with prospective US partners to begin sales of Travelan.
Travelan is based on antibodies from bovine colostrum, the 'first milk' of dairy cows which have been specifically immunised with antigens from pathogenic human bacteria and viruses, such as strains of E. coli bacteria that cause traveller's diarrhoea.
Travelan contains antibodies to 14 pathogenic strains of E. coli bacteria found in water supplies around the world.
The company is also seeking registration for Travelan in Canada, Singapore, Hong Kong, India, Thailand, Taiwan, Malaysia, the United Kingdom and Europe.
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
